Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Gain Therapeutics and keeping the price target at $8.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors related to Gain Therapeutics’ promising developments with their compound GT-02287. The imminent release of 90-day outcomes data from the Phase 1b trial in Parkinson’s disease patients is expected to provide valuable insights into the clinical activity of GT-02287, particularly its impact on functional outcomes and biomarkers. The trial has already exceeded its enrollment target, and the extension study is underway, supported by regulatory authorization in Australia.
Additionally, Gain Therapeutics plans to submit an Investigational New Drug application to the FDA, aiming to expand into Phase 2 clinical trials in the United States. Recent preclinical data presented at a scientific conference further supports GT-02287’s mechanism of action, highlighting its potential as a disease-modifying therapy for Parkinson’s disease. These developments, combined with the potential for GT-02287 to slow disease progression over a 12-month treatment period, underpin the Buy rating and the 12-month price target of $8.
In another report released on November 20, BTIG also maintained a Buy rating on the stock with a $5.00 price target.